Global Venous Thromboembolism Therapeutics Market 2017-2021


#1027808

82pages

Technavio

$ 3500

In Stock

About Venous Thromboembolism Therapeutic

The global VTE therapeutics market is expected to benefit from the growing incidence of VTE worldwide. According to the CDC, every year around 0.9 million individuals are affected by VTE in the US and 60,000 to 100,000 individuals in the US die of VTE. Further, the presence of high unmet medical needs is expected to fuel the market growth. For instance, according to the CDC approximately 50% of individuals with VTE will have long-term complications, and 33% of individuals will have a recurrence within ten years.

Technavios analysts forecast the global venous thromboembolism therapeutic market to grow at a CAGR of 6.40% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global venous thromboembolism therapeutic market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of VTE products in the following drug classes.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Venous Thromboembolism Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Bayer HealthCare
BMS
Boehringer Ingelheim
Daiichi Sankyo
Johnson & Johnson
Sanofi
Other prominent vendors
Altor Bioscience
Armetheon
Aspen Pharma
BioInvent International
eXIthera Pharmaceuticals
Gamma Therapeutics
GlycoMimetics
Green Cross
Isis Pharmaceutical
Leo Pharma
Pfizer
Portola Pharmaceuticals
ThromboGenics

Market driver
Increasing surgical procedures such as hip and knee replacements.
For a full, detailed list, view our report

Market challenge
Presence of alternatives such as thrombectomy and percutaneous techniques.
For a full, detailed list, view our report

Market trend
Development of drugs for new indications.
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
Table of Contents

PART 01: Executive summary

PART 02: Scope of the report


Market overview
Top-vendor offerings


PART 03: Market research methodology


Research methodology
Economic indicators


PART 04: Introduction


Key market highlights
Highlights


PART 05: Disease overview


Diagnosis of VTE
Treatment of VTE


PART 06: Pipeline analysis

PART 07: Market landscape


Market overview
Five forces analysis


PART 08: Market segmentation by drug class


Factor Xa inhibitors
Direct thrombin inhibitors
Heparin
Vitamin K antagonists


PART 09: Geographical segmentation


VTE therapeutics market in Americas
VTE therapeutics market in EMEA
VTE therapeutics market in APAC


PART 10: Market drivers


Increasing adoption of NOACs
Increasing surgical procedures such as hip and knee replacements
Large patient pool coupled with growing awareness campaigns


PART 11: Impact of drivers

PART 12: Market challenges


Presence of alternatives such as thrombectomy and percutaneous techniques
Unmet needs for anticoagulant reversal agents
Extensive use of generic products


PART 13: Impact of drivers and challenges

PART 14: Market trends


Development of drugs for new indications
Growing focus on emerging economies
Patient assistance programs


PART 15: Vendor landscape


Competitive scenario


PART 16: Key vendor analysis


Bayer HealthCare
BMS
Boehringer Ingelheim
Daiichi Sankyo
Johnson & Johnson
Sanofi
Other prominent vendors


PART 17: Appendix


List of abbreviations


PART 18: Explore Technavio
List of Exhibits

Exhibit 01: Product offerings

Exhibit 02: Types of venous thromboembolism

Exhibit 03: Pipeline analysis

Exhibit 04: Key pipeline molecules

Exhibit 05: Global VTE therapeutics market snapshot

Exhibit 06: Global VTE therapeutics market 2016-2021 ($ millions)

Exhibit 07: Opportunity analysis in global venous thromboembolism market

Exhibit 08: Five forces analysis

Exhibit 09: Factor Xa inhibitors in global VTE therapeutics market 2016-2021 ($ millions)

Exhibit 10: Direct thrombin inhibitors in venous thromboembolism market 2016-2021 ($ millions)

Exhibit 11: Heparin in global VTE therapeutics market 2016-2021 ($ millions)

Exhibit 12: Vitamin K antagonists in global venous thromboembolism market 2016-2021 ($ millions)

Exhibit 13: Segmentation of global VTE therapeutics market based on geography 2016 and 2021

Exhibit 14: VTE therapeutics market revenue by geography 2016-2021 (%)

Exhibit 15: Market scenario in Americas

Exhibit 16: VTE therapeutics market in Americas 2016-2021 ($ millions)

Exhibit 17: Market scenario in EMEA

Exhibit 18: VTE therapeutics market in EMEA ($ millions)

Exhibit 19: Market scenario in APAC

Exhibit 20: Venous thromboembolism therapeutics market in APAC ($ millions)

Exhibit 21: Impact of drivers

Exhibit 22: Forcefield analysis of drivers and challenges

Exhibit 23: Impact of drivers and challenges

Exhibit 24: Competitive structure analysis of global VTE therapeutics market 2015

Exhibit 25: Competitive analysis of global VTE therapeutics market 2016

Exhibit 26: Market share analysis 2015

Exhibit 27: Market penetration of various VTE manufacturers worldwide 2016

Exhibit 28: Strategic success factors of companies in global VTE therapeutics market

Exhibit 29: Bayer HealthCare: Key highlights

Exhibit 30: Bayer HealthCare: Strength assessment

Exhibit 31: Bayer HealthCare: Strategy assessment

Exhibit 32: Bayer HealthCare: Opportunity assessment

Exhibit 33: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2013-2015 ($ billions)

Exhibit 34: BMS: Key highlights

Exhibit 35: BMS: Strength assessment

Exhibit 36: BMS: Strategy assessment

Exhibit 37: BMS: Opportunity assessment

Exhibit 38: BMS: YoY revenue and growth rate of Eliquis (outside the US) 2013-2015 ($ millions)

Exhibit 39: Geographic segmentation of Eliquis 2015

Exhibit 40: Boehringer Ingelheim: Key highlights

Exhibit 41: Boehringer Ingelheim: Strength assessment

Exhibit 42: Boehringer Ingelheim: Strategy assessment

Exhibit 43: Boehringer Ingelheim: Opportunity assessment

Exhibit 44: Boehringer Ingelheim: YoY revenue and growth rate of Pradaxa (Global) 2013-2015 ($ billions)

Exhibit 45: Daiichi Sankyo: Key highlights

Exhibit 46: Daiichi Sankyo: Strength assessment

Exhibit 47: Daiichi Sankyo: Strategy assessment

Exhibit 48: Daiichi Sankyo: Opportunity assessment

Exhibit 49: Johnson & Johnson: Key highlights

Exhibit 50: Johnson & Johnson: Strength assessment

Exhibit 51: Johnson & Johnson: Strategy assessment

Exhibit 52: Johnson & Johnson: Opportunity assessment

Exhibit 53: Johnson & Johnson: YoY revenue and growth rate of Xarelto 2013-2015 ($ millions)

Exhibit 54: Sanofi: Key highlights

Exhibit 55: Sanofi: Strength assessment

Exhibit 56: Sanofi: Strategy assessment

Exhibit 57: Sanofi: Opportunity assessment

Exhibit 58: Sanofi: YoY revenue and growth rate of Lovenox 2013-2015 ($ billions)

Exhibit 59: Geographical segmentation of Lovenox 2015